Skip to content

Author

A. Holzgreve

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Influence of increased injected activities up 9.0 GBq [177Lu]Lu-PSMA-I&T on absorbed doses to lesions and kidneys

Administration activities of 177Lu-PSMA were chosen cautiously in the treatment of advanced prostate cancer. The primary aim was to investigate the association between increased injected activities, and the calculated absorbed doses (AD). In this single center, retrospective analysis, patients with PSMA-avid metastatic...

Z. Ells, Linus Hempel, J. Ells et al. · 0 citations
Open access Oct 2026

Organ-specific depth of response to CD19-directed CAR T-cell therapy in B-cell lymphomas

CD19-directed chimeric antigen receptor T cell therapy (CART) has transformed treatment of relapsed or refractory (r/r) large B cell lymphoma (LBCL); however, organ-specific response patterns and depth of response (DoR) remain insufficiently characterized. This study evaluated organ-specific imaging response and the im...

M. Kassube, P. Achhammer, Philipp Linden et al. · 0 citations
Open access Oct 2026

Long-term effects of [177Lu]Lu-PSMA therapy on the kidneys based on cumulative absorbed dose

177 Lu-PSMA radiopharmaceutical therapy shows favorable clinical responses for metastatic castration-resistant prostate cancer patients but may cause radiation-induced kidney damage due to specific and nonspecific activity accumulation. We evaluated the association between cumulative kidney absorbed doses and...

Z. Ells, Mu-Yu Wu, Linus Hempel et al. · 0 citations
Open access Aug 2026

Impact of structured reporting on interpretability of PSMA PET/CT in prostate cancer staging—towards standardised clinical implementation

This study assessed the impact of structured reporting (SR) compared with conventional free-text reporting (FTR) on report quality for PSMA PET/CT for diagnosis and staging of prostate cancer (PC) using a dedicated template. Fifty consecutive patients were included. Original clinical FTRs were compared with SRs retrosp...

Gloria Biechele, M. Schnitzer, Romy Göbel et al. · 0 citations
Open access Sep 2026

Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic Study

Background: The incremental value of PSMA PET/CT over multiparametric MRI (mpMRI) for selecting patients for prostate cancer focal therapy is undefined. Unlike lesion-detection studies, we evaluated whether PSMA PET/CT, mpMRI, and their combination correctly determine focal therapy eligibility when validated against wh...

I. Sonni, Zahra Mohammadigoldar, G. Furey et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.